Market capitalization | CHF6.20b |
Enterprise Value | CHF5.91b |
PER (TTM) P/E ratio | 55.44 |
EV/FCF (TTM) EV/FCF | negative |
EV/Sales (TTM) EV/Sales | 10.23 |
P/S ratio (TTM) P/S ratio | 10.75 |
P/B ratio (TTM) P/B ratio | 4.70 |
Dividend yield | 0.97% |
Last dividend (FY23) | CHF0.80 |
As a free StocksGuide basic user, you can view the scores for all 6,953 shares worldwide.
5 Analysts have issued a Bachem Holding forecast:
5 Analysts have issued a Bachem Holding forecast:
Dec '23 |
+/-
%
|
||
Net profit | 112 112 |
11%
11%
|
|
Depreciation and amortization | 37 37 |
12%
12%
|
|
Share compensation | 1.32 1.32 |
76%
76%
|
|
Operating cash flow | 251 251 |
171%
171%
|
|
Investments | 268 268 |
89%
89%
|
|
Dividend paid | 56 56 |
9%
9%
|
|
Free cash flow | -14 -14 |
70%
70%
|
Figures in millions CHF.
If you wish, you can receive an e-mail every morning in time for breakfast containing all the stock news relevant to you.
Bachem Holding AG engages in the provision of peptides and oligonucleotides. It operates through the Europe/Asia and North America geographical segments. It offers project management, research grade production, catalog peptides, peptide NCES, and commercial NCES. The company was founded in 2003 and is headquartered in Bubendorf, Switzerland.
Head office | Switzerland |
CEO | Thomas Meier |
Employees | 2,006 |
Founded | 2003 |
Website | www.bachem.com |
StocksGuide is the tool for easily finding, analyzing and monitoring shares. Learn from successful investors and make well-founded investment decisions. We make you a self-determined investor.